14.28
-3.57 (-20.00%)
| Penutupan Terdahulu | 17.85 |
| Buka | 14.90 |
| Jumlah Dagangan | 4,630,065 |
| Purata Dagangan (3B) | 1,582,371 |
| Modal Pasaran | 1,653,923,072 |
| Harga / Jualan (P/S) | 2.38 |
| Harga / Buku (P/B) | 5.00 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 23 Jul 2026 |
| Margin Keuntungan | -26.41% |
| Margin Operasi (TTM) | -24.43% |
| EPS Cair (TTM) | -1.51 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 11.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 192.49% |
| Nisbah Semasa (MRQ) | 1.47 |
| Aliran Tunai Operasi (OCF TTM) | -30.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 16.94 M |
| Pulangan Atas Aset (ROA TTM) | -8.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.52% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Menurun |
| Medical Devices (Global) | Bercampur | Menurun | |
| Stok | NovoCure Limited | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.13 |
|
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.84% |
| % Dimiliki oleh Institusi | 87.40% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |